• Clinical Insights

August 2023 drug trend report

Aug 2nd, 2023

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market.

Brand name drug launches*

Uzedy

  • Indicated for: Treatment of schizophrenia in adults.
  • Dosage form: Extended-release injectable suspension.
  • Status: Available now.

Abilify Asimtuffii

  • Indicated for: Treatment of schizophrenia in adults and as a maintenance monotherapy treatment of bipolar I disorder in adults.
  • Dosage form: Long-acting injectable.
  • Status: Available now.

Brixadi

  • Indicated for: Treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
  • Dosage form: Extended-release injectable.
  • Status: Expected September of 2023 (Genoa is working to become a REMS-certified pharmacy to dispense Brixadi).

Generic drug launches*

Vyvanse capsules and chewable tablets (Lisdexamfetamine Dimesylate)

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) in adults and children 6 years of age and older.
  • Status: Expected August 25, 2023.

Current drug shortages*

Brand:

Adderall

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) and/or narcolepsy.
  • Status: Estimated recovery December 2023.

Mounjaro

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Ozempic

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Generic:

Lorazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Estimated recovery August 2023

Clonazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Recovery TBD.

Divalproex DR 500mg

  • Indicated for: Treatment of bipolar disorder, migraines, and other indications.
  • Status: Recovery TBD.

*Information on this page was accurate at the time of posting. Shortage recovery dates are only estimates. These estimates are based on the distribution information that Genoa has access to.

Recent Posts


  • Blog Post
In-house, pharmacy management partnership or outsource? Questions to ask before choosing an on-site pharmacy model

Want to compare your options quickly? Download this overview. You’ve probably heard the benefits of adding a pharmacist to your care team. On-site pharmacies help break down barriers to care,...

  • Blog Post
340B made easy: 5 traits to look for in a contract pharmacy partner

The 340B Drug Pricing Program helps participating organizations – or covered entities – use savings on prescription drug costs to offer more comprehensive services and care for more eligible patients....

  • Blog Post
340B 101: What your clinic needs to know

For qualified clinics and organizations, the 340B Drug Pricing Program offers savings on prescription drug costs, helping boost offerings and outcomes for people who need it most. Wondering if your...

  • Blog Post
  • Webinar
The 340B Program information you’re looking for

For qualified clinics and organizations, the 340B Drug Pricing Program offers savings on prescription drug costs, helping boost offerings and outcomes for people who need it most. Wondering if your...